These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 35226630)
61. Oral treatment options for patients with urinary tract infections caused by extended spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae. Raja NS J Infect Public Health; 2019; 12(6):843-846. PubMed ID: 31176606 [TBL] [Abstract][Full Text] [Related]
62. Risk factors for gentamicin-resistant E. coli in children with community-acquired urinary tract infection. Roldan-Masedo E; Sainz T; Gutierrez-Arroyo A; Gomez-Gil RM; Ballesteros E; Escosa L; Baquero-Artigao F; Méndez-Echevarría A Eur J Clin Microbiol Infect Dis; 2019 Nov; 38(11):2097-2102. PubMed ID: 31359255 [TBL] [Abstract][Full Text] [Related]
63. International travel increases risk of urinary tract infection caused by extended-spectrum beta-lactamase-producing Enterobacterales-three-arm case-control study. Patjas A; Martelius A; Ollgren J; Kantele A J Travel Med; 2024 Jan; 31(1):. PubMed ID: 38123504 [TBL] [Abstract][Full Text] [Related]
64. [Urinary Tract Infections Caused by Community-Acquired Extended-Spectrum β-Lactamase-Producing Enterobacteriaceae in a Level III Hospital - A Retrospective Study]. Simões A; Lima M; Brett A; Queiroz C; Chaves C; Oliveira H; Januário L; Rodrigues F Acta Med Port; 2020 Jul; 33(7-8):466-474. PubMed ID: 31962058 [TBL] [Abstract][Full Text] [Related]
65. Risk factors for community-acquired urinary tract infection caused by ESBL-producing bacteria in children. Kizilca O; Siraneci R; Yilmaz A; Hatipoglu N; Ozturk E; Kiyak A; Ozkok D Pediatr Int; 2012 Dec; 54(6):858-62. PubMed ID: 22882781 [TBL] [Abstract][Full Text] [Related]
66. Efficacy of non-carbapenem antibiotics for pediatric patients with first febrile urinary tract infection due to extended-spectrum beta-lactamase-producing Escherichia coli. Abe Y; Inan-Erdogan I; Fukuchi K; Wakabayashi H; Ogawa Y; Hibino S; Sakurai S; Matsuhashi K; Watanabe Y; Hashimoto K; Ugajin K; Itabashi K J Infect Chemother; 2017 Aug; 23(8):517-522. PubMed ID: 28528936 [TBL] [Abstract][Full Text] [Related]
67. High Rates of ESBL-producing and Gentamycin-resistant Gram-negative Bacteria During the First Week of Life: A Multicenter Cross-sectional Study Among Infants Younger Than 2 Months With Urinary Tract Infection. Washahi M; Miron D; Steinberg Ben Zeev Z; Chayen G; Jacob R Pediatr Infect Dis J; 2023 Sep; 42(9):750-753. PubMed ID: 37257122 [TBL] [Abstract][Full Text] [Related]
69. Treatment of urinary tract infections among febrile young children with daily intravenous antibiotic therapy at a day treatment center. Gauthier M; Chevalier I; Sterescu A; Bergeron S; Brunet S; Taddeo D Pediatrics; 2004 Oct; 114(4):e469-76. PubMed ID: 15466073 [TBL] [Abstract][Full Text] [Related]
70. Impact of extended-spectrum β-lactamase-producing organisms on clinical and economic outcomes in patients with urinary tract infection. MacVane SH; Tuttle LO; Nicolau DP J Hosp Med; 2014 Apr; 9(4):232-8. PubMed ID: 24464783 [TBL] [Abstract][Full Text] [Related]
71. Molecular characterization of Extended-spectrum β lactamase- producing E. coli recovered from community-acquired urinary tract infections in Upper Egypt. Hassuna NA; Khairalla AS; Farahat EM; Hammad AM; Abdel-Fattah M Sci Rep; 2020 Feb; 10(1):2772. PubMed ID: 32066805 [TBL] [Abstract][Full Text] [Related]
72. Community infections caused by extended-spectrum beta-lactamase-producing Escherichia coli. Rodríguez-Baño J; Alcalá JC; Cisneros JM; Grill F; Oliver A; Horcajada JP; Tórtola T; Mirelis B; Navarro G; Cuenca M; Esteve M; Peña C; Llanos AC; Cantón R; Pascual A Arch Intern Med; 2008 Sep; 168(17):1897-902. PubMed ID: 18809817 [TBL] [Abstract][Full Text] [Related]
74. Increasing prevalence of ciprofloxacin resistance in extended-spectrum-β-lactamase-producing Escherichia coli urinary isolates. Bonkat G; Müller G; Braissant O; Frei R; Tschudin-Suter S; Rieken M; Wyler S; Gasser TC; Bachmann A; Widmer AF World J Urol; 2013 Dec; 31(6):1427-32. PubMed ID: 23358791 [TBL] [Abstract][Full Text] [Related]
75. Risk factors and clinical impact of levofloxacin or cefazolin nonsusceptibility or ESBL production among uropathogens in adults with community-onset urinary tract infections. Wu YH; Chen PL; Hung YP; Ko WC J Microbiol Immunol Infect; 2014 Jun; 47(3):197-203. PubMed ID: 23063776 [TBL] [Abstract][Full Text] [Related]
76. Antimicrobial Resistance in Bacteria Causing Urinary Tract Infections. Salh KK Comb Chem High Throughput Screen; 2022; 25(7):1219-1229. PubMed ID: 34161207 [TBL] [Abstract][Full Text] [Related]
77. Emerging clinical role of pivmecillinam in the treatment of urinary tract infections caused by Extended Spectrum βeta-lactamase (ESBL) producing Enterobacteriaceae. Raja NS Int J Clin Pract; 2019 Sep; 73(9):1-5. PubMed ID: 31243859 [TBL] [Abstract][Full Text] [Related]
79. FACTORS ASSOCIATED WITH EXTENDED SPECTRUM β-LACTAMASE PRODUCING ESCHERICHIA COLI IN COMMUNITY-ACQUIRED URINARY TRACT INFECTION AT HOSPITAL EMERGENCY DEPARTMENT, BANGKOK, THAILAND. Savatmorigkorngul S; Poowarattanawiwit P; Sawanyawisuth K; Sittichanbuncha Y Southeast Asian J Trop Med Public Health; 2016 Mar; 47(2):227-33. PubMed ID: 27244961 [TBL] [Abstract][Full Text] [Related]
80. Etiology and antibiotic resistance patterns of community-acquired urinary tract infections in J N M C Hospital Aligarh, India. Akram M; Shahid M; Khan AU Ann Clin Microbiol Antimicrob; 2007 Mar; 6():4. PubMed ID: 17378940 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]